CGON (CG Oncology) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGON CG Oncology Inc CGON
30 GF Score
Price $77.03
GF Value $138.70
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is CG Oncology Defensive Interval Ratio?

CGON
30GF Score
CG Oncology Inc CGON
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CG Oncology (CGON) Overvalued in 2026?

Based on GuruFocus' analysis, CG Oncology stock appears to be undervalued. The current stock price of $77.03 is trading 44.5% below its estimated GF Value™ of $138.70. GuruFocus considers CG Oncology to be Possible Value Trap.

Key valuation signals for CGON:

  • Defensive Interval Ratio:
  • GF Value™: $138.70 vs. price of $77.03 (44.5% below fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the CGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
30GF Score

Get the complete analysis for CGON

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$77.03
Price
$138.70
GF Value